Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
2022
Francesco Amati | Anna Stainer | Marco Mantero | Andrea Gramegna | Edoardo Simonetta | Giulia Suigo | Antonio Voza | Anoop M. Nambiar | Umberto Cariboni | Justin Oldham | Philip L. Molyneaux | Paolo Spagnolo | Francesco Blasi | Stefano Aliberti
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood. Recent evidence suggests that the lung microbiome might influence the pathogenesis and progression of interstitial lung diseases. In recent years, the utilization of culture-independent methodologies has allowed the identification of complex and dynamic communities of microbes, in patients with interstitial lung diseases. However, the potential mechanisms by which these changes may drive disease pathogenesis and progression are largely unknown. The aim of this review is to discuss the role of the altered lung microbiome in several interstitial lung diseases. Untangling the host–microbiome interaction in the lung and airway of interstitial lung disease patients is a research priority. Thus, lung dysbiosis is a potentially treatable trait across several interstitial lung diseases, and its proper characterization and treatment might be crucial to change the natural history of these diseases and improve outcomes.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
